Free safety and evidence review
Review a peptide, GLP-1, TRT, or growth-hormone schedule before you call it a stack
Select therapies to separate approved label constraints, clinician-defined timing, FDA significant-risk concerns, and unapproved products. The output is a question list—not a protocol.
Inputs stay in your browser. PeakedLabs does not use these tools to diagnose, select treatment, recommend a dose, or interpret lab results.
Select therapies for an evidence-status and timing review
Selection does not imply endorsement. The tool never supplies a dose, stack, sequence, fasting window, or syringe conversion.
Method and sources
Transparent math, cited context
The calculations use only the values you enter and the formulas shown on the page. The sources below provide clinical and regulatory context; they do not validate a personalized treatment plan.
- 01FDA — Bulk substances that may present significant safety risks
Source for the category 2 classification and safety concerns shown for ipamorelin acetate and injectable GHK-Cu.
- 02FDA — Understanding risks of compounded drugs
Compounded drugs are not FDA-approved and are not pre-reviewed for safety, effectiveness, or quality.
- 03FDA — Concerns with unapproved GLP-1 drugs
Source for unapproved GLP-1 warnings and retatrutide/cagrilintide compounding status.
- 04Endocrine Reviews — The chronobiology of hormone administration
Supports the distinction between natural rhythms and formulation-specific hormone administration.
- 05DailyMed — Egrifta SV
Source for tesamorelin's label-defined once-daily use, narrow indication, reconstitution, and monitoring context.